Skip to content

GSK says its abacavir trials show no heart attack risk

Start anti-HIV treatment with a CD4 cell count of 350 with efavirenz and Truvada, say draft British guidelines

Genetic profile governs immune system recovery on HAART

Most patients have a trusting relationship with their doctor after starting HIV drugs

'Discordant' response to anti-HIV treatment increases risk of illness or death

Immune reconstitution seen in 10% of South Africans starting HIV treatment

Race and gender risk factors for some anti-HIV treatment side-effects

Concerns in US study over abacavir/3TC's potency in patients with a high viral load

Viral suppression improves kidney function in patients with poor baseline kidney function and low CD4 counts